Progenics Pharmaceuticals Shares Outstanding 2006-2018 | PGNX

Progenics Pharmaceuticals shares outstanding history from 2006 to 2018. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Progenics Pharmaceuticals shares outstanding for the quarter ending June 30, 2018 were 0.074B, a 5.43% increase year-over-year.
  • Progenics Pharmaceuticals 2017 shares outstanding were 0.07B, a 0.18% increase from 2016.
  • Progenics Pharmaceuticals 2016 shares outstanding were 0.07B, a 0.63% increase from 2015.
  • Progenics Pharmaceuticals 2015 shares outstanding were 0.07B, a 2.16% increase from 2014.
Progenics Pharmaceuticals Annual Shares Outstanding
(Millions of Shares)
2017 70
2016 70
2015 70
2014 68
2013 56
2012 35
2011 33
2010 33
2009 31
2008 30
2007 27
2006 26
2005 21
Progenics Pharmaceuticals Quarterly Shares Outstanding
(Millions of Shares)
Q2 2018 74
Q1 2018 73
Q4 2017 70
Q3 2017 70
Q2 2017 70
Q1 2017 70
Q4 2016 70
Q3 2016 70
Q2 2016 70
Q1 2016 70
Q4 2015 70
Q3 2015 70
Q2 2015 70
Q1 2015 70
Q4 2014 68
Q3 2014 73
Q2 2014 70
Q1 2014 64
Q4 2013 56
Q3 2013 61
Q2 2013 51
Q1 2013 50
Q4 2012 35
Q3 2012 34
Q2 2012 34
Q1 2012 34
Q4 2011 33
Q3 2011 34
Q2 2011 34
Q1 2011 33
Q4 2010 33
Q3 2010 33
Q2 2010 32
Q1 2010 32
Q4 2009 31
Q3 2009 31
Q2 2009 31
Q1 2009 31
Q4 2008 30
Q3 2008 30
Q2 2008 30
Q1 2008 30
Q4 2007 27
Q3 2007 27
Q2 2007 27
Q1 2007 26
Q4 2006 26
Q3 2006 26
Q2 2006 26
Q1 2006 25
Q4 2005 21
Q3 2005 22
Q2 2005 20
Q1 2005 17
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.454B $0.012B
Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $63.693B 10.93
Teva Pharmaceutical Industries (TEVA) Israel $21.588B 6.03
Mylan (MYL) United Kingdom $16.323B 6.94
Bausch Health Cos (BHC) Canada $8.549B 6.37
Dr Reddy's Laboratories (RDY) India $5.666B 25.31
Supernus Pharmaceuticals (SUPN) United States $2.524B 27.01
Mallinckrodt Public (MNK) United Kingdom $2.267B 3.85
Amphastar Pharmaceuticals (AMPH) United States $0.844B 121.60
Akorn (AKRX) United States $0.828B 0.00
Homology Medicines (FIXX) United States $0.740B 0.00
CymaBay Therapeutics (CBAY) United States $0.605B 0.00
Assembly Biosciences (ASMB) United States $0.589B 0.00
Voyager Therapeutics (VYGR) United States $0.488B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.480B 0.00
Corium (CORI) United States $0.455B 0.00
Teligent (TLGT) United States $0.181B 0.00
Sol-Gel Technologies (SLGL) Israel $0.121B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.111B 0.00
Aevi Genomic Medicine (GNMX) United States $0.072B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.060B 0.00
Evoke Pharma (EVOK) United States $0.043B 0.00
Acasti Pharma (ACST) Canada $0.037B 0.00
Versartis (ARAV) United States $0.036B 0.00
Agile Therapeutics (AGRX) United States $0.028B 0.00
China Pharma Holdings (CPHI) China $0.015B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.010B 0.00